全文获取类型
收费全文 | 490篇 |
免费 | 24篇 |
国内免费 | 72篇 |
专业分类
儿科学 | 9篇 |
妇产科学 | 4篇 |
基础医学 | 57篇 |
口腔科学 | 5篇 |
临床医学 | 76篇 |
内科学 | 94篇 |
皮肤病学 | 1篇 |
神经病学 | 29篇 |
特种医学 | 57篇 |
外科学 | 102篇 |
综合类 | 12篇 |
预防医学 | 44篇 |
眼科学 | 1篇 |
药学 | 66篇 |
肿瘤学 | 29篇 |
出版年
2022年 | 7篇 |
2021年 | 5篇 |
2020年 | 6篇 |
2019年 | 8篇 |
2018年 | 3篇 |
2017年 | 9篇 |
2016年 | 5篇 |
2015年 | 8篇 |
2014年 | 9篇 |
2013年 | 28篇 |
2012年 | 22篇 |
2011年 | 26篇 |
2010年 | 12篇 |
2009年 | 23篇 |
2008年 | 20篇 |
2007年 | 61篇 |
2006年 | 26篇 |
2005年 | 28篇 |
2004年 | 14篇 |
2003年 | 13篇 |
2002年 | 12篇 |
2001年 | 17篇 |
2000年 | 17篇 |
1999年 | 10篇 |
1998年 | 19篇 |
1997年 | 19篇 |
1996年 | 19篇 |
1995年 | 15篇 |
1994年 | 6篇 |
1993年 | 7篇 |
1992年 | 6篇 |
1991年 | 10篇 |
1990年 | 14篇 |
1989年 | 16篇 |
1988年 | 11篇 |
1987年 | 13篇 |
1986年 | 5篇 |
1985年 | 4篇 |
1984年 | 6篇 |
1983年 | 4篇 |
1982年 | 3篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1978年 | 4篇 |
1977年 | 5篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1965年 | 1篇 |
排序方式: 共有586条查询结果,搜索用时 0 毫秒
11.
Hugues JN Soussis J Calderon I Balasch J Anderson RA Romeu A;Recombinant LH Study Group 《Human reproduction (Oxford, England)》2005,20(3):629-635
BACKGROUND: In anovulatory women undergoing ovulation induction, addition of recombinant human LH (rLH) to FSH treatment may promote the dominance of a leading follicle when administered in the late follicular phase. The objective of this study was to find the optimal dose of rLH that can maintain the growth of a dominant follicle, whilst causing atresia of secondary follicles. METHODS: Women with infertility due to anovulation and over-responding to FSH treatment were randomized to receive, in addition to 37.5 IU recombinant human FSH (rFSH), either placebo or different doses of rLH (6.8, 13.6, 30 or 60 microg) daily for a maximum of 7 days. The primary efficacy endpoint was the proportion of patients who had exactly one follicle > or = 16 mm on hCG day. RESULTS: Among 153 enrolled patients, the five treatment groups were similar in terms of baseline characteristics. The proportion of patients with exactly one follicle > or = 16 mm ranged from 13.3% in the placebo group to 32.1% in the 30 microg rLH group (P = 0.048). The pregnancy rate ranged from 10.3% in the 60 microg group to 28.6% in the 30 microg rLH group. Adverse events were similar between groups. CONCLUSIONS: In patients over-responding to FSH during ovulation induction, doses of up to 30 microg rLH/day appear to increase the proportion of patients developing a single dominant follicle (> or = 16 mm). Our data support the 'LH ceiling' concept whereby addition of rLH is able to control development of the follicular cohort. 相似文献
12.
Harley B Messinger Egilius LH Spierings Arnaud JP Vincent John Lebbink 《Cephalalgia : an international journal of headache》1991,11(1):13-18
In two headache questionnaire surveys we inquired about the occurrence of headache in the mothers, fathers, siblings and children of the respondents. In total, 633 people completed valid questionnaires, 260 in the first survey and 373 in the second. The hypothesis was that familial headache occurrence would be positively associated with headache frequency. In each survey, the regression of headache frequency on the number of parents having headache was highly significant. Neither sex nor the sibling and children variables were significant predictors. In the cross-tabulations of the parental occurrence of headache with headache frequency we saw a clear "break-point" between the "no headache" and the headache frequency categories studied. For the final analyses the dichotomy "headache/no headache" was related in fourfold tables to headache occurrence in the father and the mother separately, and to the number of headache parents. The positive associations were not simply due to the large number of migraine cases since they remained after removing the migraineurs. 相似文献
13.
Early stage nasopharyngeal carcinoma: radiotherapy dose and time factors in tumor control 总被引:1,自引:0,他引:1
Chang JT; See LC; Liao CT; Chen LH; Leung WM; Chen SW; Chen WC 《Japanese journal of clinical oncology》1998,28(3):207-213
OBJECTIVE: To evaluate radiotherapy dose and length of treatment in the
control of early stage nasopharyngeal carcinoma (NPC) treated with a
combination of external radiotherapy and brachytherapy, MATERIALS &
METHODS: We reviewed the records of 133 patients with early stage
nasopharyngeal carcinoma (stage I or II, AJC/UICC staging system) who
received definitive radiotherapy in Chang Gung Memorial Hospital from 1979
to 1991. The median follow-up time was 7.1 years with a minimum of 2 years.
All patients were treated with megavoltage external radiotherapy to the
nasopharynx area (63-72 Gy) followed by high dose rate intracavitary
brachytherapy (5-16.5 Gy in one to three fractions, spaced 1-2 weeks
apart). The median total dose and time of irradiation was 75 Gy (69.8-81.4
Gy) and 11.6 weeks (7.8-20 weeks) respectively. Survival analysis was used
to examine the effect of several variables on prognosis. RESULTS: The
5-year rates were 86.4% for local control, 84.7% for disease free survival,
88.5% for actuarial survival and 84.2% for overall survival. The treatment
group (combination of time and dose of irradiation) was the most important
prognostic factor according to Cox's proportional hazard model. Patients
receiving radiation at a total dose of < or = 75 Gy completed in < 12
weeks showed the best prognosis. CONCLUSION: Treatment time and total
treatment dose are both important factors in treating early stage NPC.
Decreasing the total radiation time to < 12 weeks and not exceeding a
radiation dose of 75 Gy gave the best results.
相似文献
14.
15.
16.
A. Marijke Keestra Marcel R. de ZoeteLieneke I. Bouwman Mahdi M. VaeziradJos P.M. van Putten 《Developmental and comparative immunology》2013
Toll-like receptors (TLRs) are a major class of innate immune pattern recognition receptors that have a key role in immune homeostasis and the defense against infections. The research explosion that followed the discovery of TLRs more than a decade ago has boosted fundamental knowledge on the function of the immune system and the resistance against disease, providing a rational for clinical modulation of the immune response. In addition, the conserved nature of the ancient TLR system throughout the animal kingdom has enabled a comparative biology approach to understand the evolution, structural architecture, and function of TLRs. In the present review we focus on TLR biology in the avian species, and, especially, on the unique functional properties of the chicken TLR repertoire. 相似文献
17.
SG Lindquist M Duno M Batbayli A Puschmann H Braendgaard S Mardosiene K Svenstrup LH Pinborg K Vestergaard LE Hjermind J Stokholm BB Andersen P Johannsen JE Nielsen 《Clinical genetics》2013,83(3):279-283
Recently, a hexanucleotide (GGGGCC) repeat expansion in the first intron of C9ORF72 was reported as the cause of chromosome 9p21‐linked frontotemporal dementia‐amyotrophic lateral sclerosis (FTD‐ALS). We here report the prevalence of the expansion in a hospital‐based cohort and associated clinical features indicating a wider clinical spectrum of C9ORF72 disease than previously described. We studied 280 patients previously screened for mutations in genes involved in early onset autosomal dominant inherited dementia disorders. A repeat‐primed polymerase chain reaction amplification assay was used to identify pathogenic GGGGCC expansions. As a potential modifier, confirmed cases were further investigated for abnormal CAG expansions in ATXN2. A pathogenic GGGGCC expansion was identified in a total of 14 probands. Three of these presented with atypical clinical features and were previously diagnosed with clinical olivopontocerebellar degeneration (OPCD), atypical Parkinsonian syndrome (APS) and a corticobasal syndrome (CBS). Further, the pathogenic expansion was identified in six FTD patients, four patients with FTD‐ALS and one ALS patient. All confirmed cases had normal ATXN2 repeat sizes. Our study widens the clinical spectrum of C9ORF72related disease and confirms the hexanucleotide expansion as a prevalent cause of FTD‐ALS disorders. There was no indication of a modifying effect of the ATXN2 gene. 相似文献
18.
19.
20.
Abraham H. Hulst MD Maarten J. Visscher MD Marc B. Godfried PhD Bram Thiel Bastiaan M. Gerritse PhD Thierry V. Scohy PhD R. Arthur Bouwman PhD Mark G. A. Willemsen MD Markus W. Hollmann PhD Benedikt Preckel PhD J. Hans DeVries PhD Jeroen Hermanides PhD 《Diabetes, obesity & metabolism》2020,22(4):557-565